Safety and Efficacy of Lamivudine-Zidovudine Combination Therapy in Zidovudine-Experienced Patients
- 10 July 1996
- journal article
- research article
- Published by American Medical Association (AMA)
- Vol. 276 (2), 111-117
- https://doi.org/10.1001/jama.1996.03540020033026
Abstract
Objective. —To compare the safety and efficacy of 2 doses of lamivudine given in combination with zidovudine with continued zidovudine monotherapy. Design. —Double-blind, randomized, multicenter, comparative trial of 223 patients treated for 24 weeks. Setting. —Patients from 32 hospitals in Europe were enrolled throughout a 1-year period. Patients. —Adult human immunodeficiency virus type 1 (HIV-1)—positive, zidovudine-experienced (≥24 weeks prior zidovudine) patients with CD4+cell counts between 0.10 and 0.40×109/L (100-400 cells/μL). Intervention. —Patients received either 200 mg of zidovudine every 8 hours, 150 mg of lamivudine every 12 hours plus zidovudine, or 300 mg of lamivudine every 12 hours plus zidovudine for 24 weeks. All patients were then allowed to receive zidovudine and open-label lamivudine combination therapy. Twelve patients withdrew because of adverse events during the 24-week treatment period. Main Outcome Measures. —Effcacy was measured by evaluating immunological and viral load changes, and safety was assessed by evaluating clinical manifestations and laboratory indexes of toxic effects. Results. —Patients receiving low- or high-dose combination therapy had greater treatment effects compared with patients receiving continued zidovudine monotherapy during the first 24 weeks as documented by changes in CD4+cell counts (+0.04 vs +0.03 vs −0.02×109/L, respectively;P<.001); log10HIV-1 RNA as measured by the Roche assay (−0.96 vs −0.77 vs +0.07 copies/mL, respectively;P<.001) or log10HIV-1 RNA measured by the quantitative nucleic acid sequence— based amplification assay (−0.59 vs −1.06 vs −0.02 copies/mL, respectively;P<.011); and immune-complex dissociated (ICD) p24 antigen (−74% vs −68% vs +27%, respectively;P<.001). There were no statistically significant differences in viral measurements, in CD4+cell counts, or in safety profile between the groups receiving 2 doses of lamivudine in combination with zidovudine. The effects on CD4+cell counts and ICD p24 antigen were sustained throughout 48 weeks for patients continuing combination therapy. Patients switching to combination therapy at week 24 showed improvement. Conclusions. —In zidovudine-experienced HIV-1—infected patients, combination treatment with lamivudine and zidovudine is well tolerated and provides greater and more sustained increases in CD4+cell counts and decreases in viral load than continued zidovudine monotherapy.Keywords
This publication has 5 references indexed in Scilit:
- Virologic and Immunologic Benefits of Initial Combination Therapy with Zidovudine and Zalcitabine or Didanosine Compared with Zidovudine MonotherapyThe Journal of Infectious Diseases, 1996
- Targeting HIV reverse transcriptase in novel waysNature Medicine, 1995
- Prediction of progression to AIDS with serum HIV-1 RNA and CD4 countThe Lancet, 1995
- Comparing Treatment Groups on the Basis of Slopes, Areas-Under-the-Curve, and other Summary MeasuresDrug Information Journal, 1994
- Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infectionThe Lancet, 1994